Ad
related to: charcot triad in multiple sclerosis disease modifying drugs
Search results
Results from the WOW.Com Content Network
Charcot's neurologic triad is the combination of nystagmus, intention tremor, and scanning or staccato speech. This triad is associated with multiple sclerosis, where it was first described; [1] however, it is not considered pathognomonic for it. It is named after Jean-Martin Charcot. [2]
Multiple disease-modifying medications were approved by regulatory agencies for RRMS; they are modestly effective at decreasing the number of attacks. [134] Interferons [ 135 ] and glatiramer acetate are first-line treatments [ 5 ] and are roughly equivalent, reducing relapses by approximately 30%. [ 136 ]
For antioxidant therapy, studies have shown that reactive oxidative species lead to the formation of multiple sclerosis lesions in which antioxidants can help induce neuroprotective and immunomodulatory effects. [210] Probably the most clear disease modifying factor (for worse) is smoking, and therefore to quit smoking should be considered. [211]
Charcot's cholangitis triad: Right Upper Quadrant Pain, Fever, Jaundice: Ascending cholangitis: Charcot's neurologic triad: scanning speech, intention tremor, nystagmus: Multiple sclerosis: Triad of congenital toxoplasmosis: chorioretinitis, hydrocephalus, intracranial calcifications: Congenital toxoplasmosis: Triad of congenital rubella
Jean-Martin Charcot (French: [ʒɑ̃ maʁtɛ̃ ʃaʁko]; 29 November 1825 – 16 August 1893) was a French neurologist and professor of anatomical pathology. [2] He worked on groundbreaking work about hypnosis and hysteria, in particular with his hysteria patient Louise Augustine Gleizes. [3]
Charcot's neurologic triad of symptoms of multiple sclerosis; Some anterolateral central arteries in the brain are known as Charcot's artery; Neuropathic arthropathy, Charcot's joint or Charcot foot; Amyotrophic lateral sclerosis, a motor neurone disease known as both Charcot's disease and Lou Gehrig's disease
Fingolimod was approved and released on the market in USA in 2010 as an anti-multiple sclerosis drug. [11] Multiple sclerosis is an autoimmune disease where immune cells attack the neurons of the central nervous system and degrade the myelin that protect them. [12] There is no cure for multiple sclerosis, but disease modifying therapies (DMTs ...
In fact, it seems that MS patients with anti-MOG positivity could be considered a different disease in the near future. Comparative Effectiveness Research (CER) is an emerging field in Multiple Sclerosis treatment. The response of the disease to the different available medications at this moment cannot be predicted, and would be desirable. [17]
Ad
related to: charcot triad in multiple sclerosis disease modifying drugs